Risankizumab for pityriasis rubra pilaris

Clin Exp Dermatol. 2021 Oct;46(7):1322-1324. doi: 10.1111/ced.14715. Epub 2021 Jun 13.

Authors

E Brocco¹, E Laffitte¹

Affiliation

¹ Department of Dermatology, Geneva University Hospital, Geneva, Switzerland.

PMID: 33914925
DOI: 10.1111/ced.14715

No abstract available

Publication types

Letter

MeSH terms

Adult
Antibiotics, Antitubercular / therapeutic use
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / therapeutic use*
Female
Humans
Injections, Subcutaneous
Latent Tuberculosis / complications
Latent Tuberculosis / drug therapy
Pityriasis Rubra Pilaris / complications
Pityriasis Rubra Pilaris / drug therapy*
Pityriasis Rubra Pilaris / pathology
Rifampin / therapeutic use

Substances

Antibiotics, Antitubercular
Antibodies, Monoclonal
risankizumab
Rifampin